Bicara Therapeutics Common Stock Alpha and Beta Analysis
| BCAX Stock | 16.72 0.03 0.18% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Bicara Therapeutics Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Bicara Therapeutics over a specified time horizon. Remember, high Bicara Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Bicara Therapeutics' market risk premium analysis include:
Beta 0.5 | Alpha (0.15) | Risk 3.88 | Sharpe Ratio 0.0082 | Expected Return 0.0319 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Bicara Therapeutics Backtesting, Bicara Therapeutics Valuation, Bicara Therapeutics Correlation, Bicara Therapeutics Hype Analysis, Bicara Therapeutics Volatility, Bicara Therapeutics History and analyze Bicara Therapeutics Performance. Bicara Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Bicara Therapeutics market risk premium is the additional return an investor will receive from holding Bicara Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bicara Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Bicara Therapeutics' performance over market.| α | -0.15 | β | 0.50 |
Bicara Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Bicara Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Bicara Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Bicara Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Bicara Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Bicara Therapeutics shares will generate the highest return on investment. By understating and applying Bicara Therapeutics stock market price indicators, traders can identify Bicara Therapeutics position entry and exit signals to maximize returns.
Bicara Therapeutics Return and Market Media
The median price of Bicara Therapeutics for the period between Fri, Oct 24, 2025 and Thu, Jan 22, 2026 is 17.09 with a coefficient of variation of 8.21. The daily time series for the period is distributed with a sample standard deviation of 1.39, arithmetic mean of 16.97, and mean deviation of 1.14. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Discretionary transaction by Ra Capital Management, L.p. of 1172334 shares of Bicara Therapeutics subject to Rule 16b-3 | 11/04/2025 |
2 | Disposition of 8000 shares by Cohlhepp Ryan of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 11/21/2025 |
3 | Disposition of 906 shares by Raben David of Bicara Therapeutics at 18.8424 subject to Rule 16b-3 | 11/25/2025 |
4 | Insider Selling Bicara Therapeutics CEO Sells 41,163 Shares of Stock | 11/26/2025 |
5 | Bicara Therapeutics Shares Down 3.3 percent Time to Sell | 11/28/2025 |
6 | Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrol... | 12/01/2025 |
7 | Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 | 12/15/2025 |
8 | Acquisition by Mazumdar Claire of 29500 shares of Bicara Therapeutics at 5.4537 subject to Rule 16b-3 | 12/16/2025 |
9 | Disposition of 9200 shares by Hyep Ivan of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 12/22/2025 |
10 | Disposition of 19789 shares by Raben David of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 12/26/2025 |
11 | Acquisition by Raben David of 19789 shares of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 12/29/2025 |
12 | Bicara Therapeutics Rating Increased to Strong-Buy at BTIG Research | 01/09/2026 |
13 | Stock Analysts Updated EPS Estimates for January 13th | 01/13/2026 |
14 | Disposition of 149 shares by Cohlhepp Ryan of Bicara Therapeutics at 18.02 subject to Rule 16b-3 | 01/15/2026 |
15 | Disposition of 6415 shares by Hyep Ivan of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 01/16/2026 |
About Bicara Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Bicara or other stocks. Alpha measures the amount that position in Bicara Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 15.32 | 27.93 | 25.14 | 26.4 | Net Debt To EBITDA | 5.76 | 5.94 | 5.35 | 3.15 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bicara Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bicara Therapeutics' short interest history, or implied volatility extrapolated from Bicara Therapeutics options trading.
Build Portfolio with Bicara Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.